Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Ranica – page 94

2 668 clinical trials in Ranica, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Ranica at a glance
2 668
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

2 668 trials in Ranica

Open in trial search

Optic ischaemic neuropathy

Not yet recruiting

Efficacy and Safety of Intranasal Cenegermin in Adults with Non‑Arteritic Anterior Ischemic Optic Neuropathy (NAION)

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cenegermin
  • Sponsor:Dompe' Farmaceutici S.p.A.

A Phase III study of AZD0120 with drug combination versus standard therapy in adults with newly diagnosed multiple myeloma not eligible for stem cell transplant

Not yet recruiting
Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:AZD0120
  • Sponsor:AstraZeneca AB

Spinal muscular atrophy

Not yet recruiting

Safety and Efficacy of Intrathecal BIIB115 in Infants with Spinal Muscular Atrophy Previously Treated with Onasemnogene Abeparvovec

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:BIIB115
  • Sponsor:Biogen Idec Research Limited

Stargardt's disease

Not yet recruiting

Phase 3 Study of Gildeuretinol Acetate (ALK‑001) to Assess Safety and Efficacy in Slowing Progression of Stargardt Disease in Adults

Investigational
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Gildeuretinol acetate
  • Sponsor:Alkeus Pharmaceuticals Inc.

Hepatocellular carcinoma

Not yet recruiting

Advanced hepatocellular carcinoma patients: assessing atezolizumab drug combination and other treatment sequences

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Azienda Sanitaria Locale Napoli 1 Centro

Heart failure with reduced ejection fraction

Not yet recruiting

Evaluating the efficacy and safety of CRD-4730 in patients with heart failure with reduced ejection fraction

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:CRD-4730
  • Sponsor:Cardurion Pharmaceuticals Inc.

Amyotrophic lateral sclerosis

Not yet recruiting

Randomized Placebo‑Controlled Trial of Colchicine to Slow Disease Progression in Adults with Amyotrophic Lateral Sclerosis

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Colchicine
  • Sponsor:Azienda Ospedaliero Universitaria Di Modena

Acquired C1 inhibitor deficiency

Not yet recruiting

Efficacy and Safety of Berotralstat for Preventing Angioedema Attacks in Patients with Acquired Angioedema due to C1 Inhibitor Deficiency

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Berotralstat
  • Sponsor:Policlinico San Donato S.p.A.

Adenoid cystic carcinoma

Not yet recruiting

Study of Sodium Valproate and Lenvatinib in Patients with Recurrent or Metastatic Adenoid Cystic Carcinoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Lenvatinib
  • Sponsor:Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia

Breast cancer

Not yet recruiting

Premedication with dexamethasone to prevent interstitial lung disease in breast cancer patients receiving trastuzumab deruxtecan

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Istituto Di Ricerche Farmacologiche Mario Negri

Arrhythmic storm

Not yet recruiting

Efficacy of bupivacaine hydrochloride and lidocaine hydrochloride compared with amiodarone hydrochloride as first‑line treatment for electrical storm in patients

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Amiodarone Hydrochloride
  • Sponsor:Fondazione IRCCS Policlinico San Matteo

Acute myeloid leukaemia+1

Not yet recruiting

Safety and feasibility study of CARCIK‑CD123/33 cell therapy in adult and pediatric patients with relapsed or refractory AML and BPDCN

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:CARCIK-CD123/33
  • Sponsor:Fondazione IRCCS San Gerardo Dei Tintori

Other cities in Italy

The busiest research cities in the country

All 230 cities in Italy

Clinical research in Ranica

What the registry says about research in the country

01 Glomerulonephritis Studies

Innovative research focusing on membranoproliferative glomerulonephritis and related conditions, evaluating novel therapeutic approaches including iptacopan and pegcetacoplan for treating various forms of kidney inflammation.

  • IC-MPGN Treatment Evaluation
  • C3 Glomerulopathy Research
  • Post-Transplant Recurrence Studies

Multiple trials aim to reduce proteinuria and improve long-term kidney function outcomes.

02 Nephropathy Research

Comprehensive studies examining treatments for IgA Nephropathy and membranous nephropathy, including investigations of sparsentan and specialized antibody therapies for patients resistant to conventional treatments.

  • Primary Membranous Nephropathy
  • IgA Nephropathy Interventions
  • Antibody-Based Treatments

Focus on proteinuria reduction and preservation of renal function in various nephropathy types.

03 Chronic Kidney Disease

Advanced research into non-diabetic chronic kidney disease, exploring new therapeutic options including finerenone and investigating treatments for complications like hyperkalemia.

  • Disease Progression Prevention
  • Hyperkalemia Management
  • Long-term Kidney Function

Studies aim to delay disease progression and improve standard of care outcomes.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.